Search
Copper
go.drugbank.com/drugs/DB09130ApprovedInvestigationalCopper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label]. Copper is commonly used in contraceptiv...
Mixtures: Kamu Jay Multi Complex Tab, Calcium With Mg Zn Mn Cu CR Si and Vit. C & DNalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigationalNirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CL<sup>PRO</sup>) inhibitor that is the subject of clinical trial NCT04756531. … [L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesHydrocodone
go.drugbank.com/drugs/DB00956ApprovedIllicitInvestigationalHydrocodone's more potent metabolite, [hydromorphone] has also found wide use as an analgesic and is frequently used in cases of severe pain.
Mixtures: P-Tuss, Novahistex DhCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesCinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalCinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. … First synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalThe novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform neurofibromas (PN … NF-1 is considered rare, with an estimated incidence of 1/3000 individuals.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalhamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalhamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnIt was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesThonzylamine
go.drugbank.com/drugs/DB11235ApprovedThonzylamine is an antihistamine and anticholinergic drug.
Mixtures: Poly-Hist DM, Nasopen PE